Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDRX 
Veradigm Inc. (MDRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: MDRX (1-star) is a SELL. SELL since 2 days. Simulated Profits (1.09%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.83
1 Year Target Price $5.83
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.69% | Avg. Invested days 51 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 526.71M USD | Price to earnings Ratio - | 1Y Target Price 5.83 |
Price to earnings Ratio - | 1Y Target Price 5.83 | ||
Volume (30-day avg) 3 | Beta 0.71 | 52 Weeks Range 3.00 - 11.80 | Updated Date 09/16/2025 |
52 Weeks Range 3.00 - 11.80 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -14.7% | Operating Margin (TTM) 16.59% |
Management Effectiveness
Return on Assets (TTM) -0.62% | Return on Equity (TTM) -1.69% |
Valuation
Trailing PE - | Forward PE 15.17 | Enterprise Value 288700000 | Price to Sales(TTM) 0.9 |
Enterprise Value 288700000 | Price to Sales(TTM) 0.9 | ||
Enterprise Value to Revenue 0.49 | Enterprise Value to EBITDA 4.94 | Shares Outstanding 108600000 | Shares Floating 81476919 |
Shares Outstanding 108600000 | Shares Floating 81476919 | ||
Percent Insiders 4.28 | Percent Institutions 41.94 |
Upturn AI SWOT
Veradigm Inc.
Company Overview
History and Background
Veradigm Inc. (formerly Allscripts Healthcare Solutions, Inc.) was founded in 1986. It has evolved through acquisitions and organic growth, becoming a provider of healthcare information technology solutions. Key milestones include the mergers of Misys Healthcare Systems and Allscripts in 2008 and the rebranding to Veradigm in 2018.
Core Business Areas
- Provider Solutions: Offers electronic health record (EHR), practice management, and revenue cycle management solutions for physician practices, hospitals, and other healthcare providers.
- Payer Solutions: Provides solutions for payers, including data analytics, risk adjustment, and quality reporting.
- Data and Analytics Solutions: Offers data and analytics solutions to healthcare organizations, life sciences companies, and government agencies, leveraging a large network of healthcare data.
- Veradigm Network: Connects payers, providers, and patients, allowing for the secure exchange of healthcare information and facilitating value-based care.
Leadership and Structure
The CEO is Dr. Yin Ho. The company has a board of directors and a structured leadership team overseeing different business segments, including technology, sales, and operations.
Top Products and Market Share
Key Offerings
- Veradigm EHR: An electronic health record (EHR) system used by physician practices. Market share data is difficult to ascertain precisely, but Veradigm is a major player. Competitors: Epic Systems, Cerner, athenahealth.
- Veradigm Payer Analytics: Data analytics solutions for payers to manage risk and improve quality. Revenue figures are not publicly broken out specifically for this product. Competitors: Optum, Cognizant, Change Healthcare (now part of Optum).
- Veradigm AccelRx: Helps facilitate electronic prior authorizations. Competitors: CoverMyMeds (owned by McKesson), Surescripts.
Market Dynamics
Industry Overview
The healthcare IT industry is characterized by increasing demand for interoperability, data analytics, and value-based care solutions. Regulatory mandates such as the 21st Century Cures Act are driving adoption of new technologies.
Positioning
Veradigm is positioned as a provider of integrated healthcare IT solutions, focusing on connecting payers, providers, and patients. Its competitive advantage lies in its data network and established customer base.
Total Addressable Market (TAM)
The global healthcare IT market is projected to reach hundreds of billions of dollars. Veradigm's position with its wide range of solutions provides for substantial growth, however, it is impacted by significant competition.
Upturn SWOT Analysis
Strengths
- Large installed customer base
- Extensive healthcare data network
- Integrated suite of solutions
- Strong brand recognition
- Established relationships with payers and providers
Weaknesses
- Past legal issues and controversies
- Integration challenges with acquired companies
- High debt load
- Intense competition
- Dependence on legacy systems
Opportunities
- Expanding into new markets and geographies
- Developing new data analytics and AI-powered solutions
- Leveraging its data network to support value-based care
- Acquiring complementary businesses
- Partnering with other technology companies
Threats
- Increasing competition from larger and more established players
- Regulatory changes and compliance requirements
- Data security and privacy concerns
- Economic downturn
- Consolidation in the healthcare industry
Competitors and Market Share
Key Competitors
- EPIC
- CERN
- ATHA
Competitive Landscape
Veradigm faces stiff competition from larger, more established players. Its strengths lie in its data network and integrated solutions, but it needs to address its debt load and integration challenges.
Major Acquisitions
Pulse8
- Year: 2020
- Acquisition Price (USD millions): 185
- Strategic Rationale: Enhanced payer solutions with advanced analytics and risk adjustment capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent due to acquisitions, divestitures, and industry changes.
Future Projections: Future growth is projected to be driven by demand for data analytics, value-based care, and interoperability solutions.
Recent Initiatives: Recent initiatives include strategic acquisitions, partnerships, and new product launches.
Summary
Veradigm is a significant player in the healthcare IT space with a large customer base and extensive data network. However, the company faces strong competition, past legal issues, and needs to focus on integrating acquisitions and reducing its debt load. The growing demand for data analytics and value-based care presents substantial opportunities for future growth. The overall health of the company is slightly above average given its opportunity.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and financial information are subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Veradigm Inc.
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 1999-07-26 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2450 | Website https://veradigm.com |
Full time employees 2450 | Website https://veradigm.com | ||
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS, EHR software, veradigm EHR, and practice fusion EHR; and patient engagement platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as veradigm connect, veradigm app expo, and diagnostic ordering and resulting network; life sciences, health plans and payers, and providers; and veradigm eprescribe enterprise. In addition, the company offers risk adjustment solutions, such as health equity analytics, risk adjustment analytics, risk mitigator, comprehensive submissions, and utilization analytics; quality analytics, risk adjustment, and quality management; data exchange and coding solutions, including echart courier, echart coder, and echart integration and analytics; clinical data registries for physicians and veradigm payer insights; provider engagement solutions; care gap alerting, gap closure services, and veradigm payerpath solutions. Further, it provides real world data solutions, such as NLP-enriched EHR data solutions, and clinical data registries; real world evidence and real-world evidence analytics platform; and digital health media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.